Business Wire

TECKRO

29.9.2021 15:06:05 CEST | Business Wire | Press release

Share
Teckro Launches Next-Generation Clinical Trial Mobile Platform, Giving Site Staff Faster Answers in Fewer Clicks

Teckro, the creator of the only clinical trials platform that facilitates collaboration and real-time decision-making between and among stakeholders, announces new product capabilities to accelerate site adoption of modern trial practices, making communication even easier at the point of care. A next-generation mobile app gives investigators and site staff answers in fewer clicks, while platform enhancements will result in new studies operational on Teckro in half the time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005472/en/

Toward its vision of engaging every physician in clinical research, Teckro also unveils its “Teckro Powered” site program to establish a community of research sites ready to advance the industry and help shape future product requirements. Today, more than 23,000 research sites around the world rely on the Teckro platform for clinical trials in all therapeutic areas.

“With a critical mass of sites using Teckro, we deepen our commitment to a simple, site-driven experience that allows physicians to easily engage in research without compromising time caring for patients,” says Teckro CEO Gary Hughes. “Sponsors can ease the complexity of clinical trials with a frictionless way to communicate with sites, including when investigators can receive direct guidance from study experts at the point of care.”

First-Of-Its-Kind Site Program: Teckro Powered

“Teckro Powered” is a novel program open to any research site. The program includes a dedicated sandbox to preview Teckro capabilities and input into future requirements. In addition with the program, sites and site networks can:

  • Build a technology-ready brand. Teckro Powered sites are technically savvy. Designated with a program badge on their websites and social media platforms, sites can use this to differentiate themselves and build their reputations as “sites of choice” for sponsors.
  • Expand physician participation in research. Behind the Teckro Powered program is a community of research sites to open a new way to collaborate and advance the industry. With the strength of a Teckro Powered community, the goal is to encourage more physicians to participate in clinical trials, reaching broader, diverse patient populations.
  • Limit impact of staff turnover. Teckro Powered is a way for sites to mitigate disruption from staff turnover. With study resources conveniently hosted in Teckro and accessible from a smartphone, sites can simplify new study member onboarding. A central source for content, communication and collaboration reduces the time to train new staff over the course of a trial.

“The Teckro Powered program fills a gap in the industry,” says Director of Site Strategy Silvina Baudino. “Working with sites for almost 20 years, I know how challenging clinical research can be. Teckro is dedicated to the site experience, which you see in both the new product capabilities and the investment in the Teckro Powered program. We are creating a way for sites to differentiate themselves and participate in a community of research sites.”

Maximizing Sponsor-Site Collaboration

Teckro’s latest platform enhancements go toward solving gaps in communication and easing the burden on site staff. A hub for study content and communication, the new Teckro capabilities include:

  • Next-generation mobile application. The streamlined app provides a simple, mobile-first user experience to support point of care decisions. Based on deep user research, the new mobile application is optimally designed for clinical trial answers in just a couple of clicks. The new Teckro mobile app is now available in the app stores for Apple and Android smartphones.
  • Diverse experts on demand . Teckro is expanding its communication to support more granular groups of experts for different types of site queries. Real-time guidance from those best suited to provide answers eliminates the need for a “switchboard” or for study monitors to operate as a go-between. The feature will be available in the fourth quarter.
  • Increased speed and scale. Underlying platform improvements mean new studies can be added in half the time. This allows sponsors to standardize on Teckro as a resource for their sites to access current study content and communications across trials.

Meet Teckro at the Global Site Solution Summit
Teckro is a sponsor at the upcoming Global Site Solution Summit (October 1-3). Visit us at Booth 716 to see a demo and talk with our experts. You can also request a meeting with Silvina Baudino (Teckro director of site strategy) or Malia Lewin (Teckro global head of strategy) by completing the form on our event page . Silvina will also participate as a panelist in the breakout session “It's Not You, It's Me: How to Manage Long-Term Partnerships” on both October 2 at 1:30 p.m. and October 3 at 9 a.m.

About Teckro
Recognized as one of the fastest growing clinical trial start-ups, Teckro transforms the study protocol into a hub of communication and collaboration. It’s a digital platform that connects all study stakeholders with the knowledge they need, when they need it. Thousands of investigators and more than 23,000 sites around the world rely on Teckro to execute clinical trials from biopharma sponsors, including 12 out of the Top 20 pharma companies. Teckro supports all therapeutic areas, all phases, and any trial format ranging from traditional in-clinic, decentralized clinical trials, or a hybrid approach.

More Information

Link:

ClickThru

Social Media:

https://www.facebook.com/teckroofficial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Virtual Installation The Kuutar Garden by Jakob Kudsk Steensen Opens in Oulu, Finland, in September10.9.2026 13:37:00 CEST | Press release

Deep underneath the city centre of Oulu, Danish artist Jakob Kudsk Steensen’s site-specific installation The Kuutar Garden comes to life on 18 September as part of the Oulu2026 European Capital of Culture programme, featuring musical collaborations with Danny L Harle and vocalist yeule. “The Kuutar Garden evokes a new ecological reality, unrooted from our physical boundaries, into a rhythmic and ghost-like world nurtured by a moonlight illuminated botanical garden. I hope audiences feel connected to the emergence of new worlds, and the caring of overlooked plant life,” says Steensen. The Kuutar Garden emerges from over four years of ecological fieldwork within the Botanical Garden of the University of Oulu, one of the world's northernmost botanic gardens, where Steensen bore witness to subarctic winters set against the artificial glow of greenhouse architecture. From this encounter, Steensen has conjured a virtual replica of that architecture, carrying audiences into an otherworldly re

New Circularity Data: Nine Out of Ten Returned Items Lose Value for Retailers10.9.2026 13:33:00 CEST | Press release

New research finds 86% of retailers have established circularity practices, yet only 9% resell more than half of returned products at full price New research from ReBound Returns and Advanced Supply Chain (ASC) has revealed a gap between retailers’ circularity ambitions and the value they are recovering from returned products. The Circularity Index, based on research among 150 senior leaders at mid-to-large UK and European retailers, found that 86% have an established approach to circularity in returns, with practices including resale, refurbishment, repair and recycling regularly used across the business. For 27%, circularity is a core part of how returns are managed. However, translating those strategies into commercial value remains difficult. On average, 12% of returned items generate no value, while only 9% of retailers resell more than half of their returned products at full price. There is also a significant opportunity still to be captured. 82% of retailers believe that up to h

One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie10.9.2026 13:02:00 CEST | Press release

One Biosciences, a techbio company spun off from Institut Curie pioneering clinical-grade single-cell tumor profiling, and Institut Curie, the leading French center for the fight against cancer, today announced support from Bpifrance through the France 2030 i-Démo1 program for the CAST project (Cancer Single-cell Analysis for Therapy), securing €3,3 Million in funding. This milestone marks a major step forward in the development of single-cell tumor profiling technology for routine cancer care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910763012/en/ Triple-negative breast cancer (TNBC) represents approximately 15–20% of breast cancer cases. Patients face high relapse rates, rapid disease progression and limited treatment options, while clinicians still lack reliable biomarkers to predict which patients will respond to immunotherapy or chemotherapy combinations. Current diagnostic approaches average signals across mil

New WSJ Intelligence Survey Highlights the Human Skills Companies Must Protect as AI Enters the Workplace10.9.2026 13:00:00 CEST | Press release

The Cognition Index Research Report, launched in partnership with Philip Morris International, warns of “Cognitive Atrophy” and a growing AI trust gap in the workplace Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today unveiled The Cognition Index Research Report, a comprehensive study exploring the evolving role of human cognition in an AI-driven workplace. Surveying more than 2,500 business professionals across the United States, United Kingdom, Italy, South Africa, and Brazil, the report reveals that while business professionals are increasingly optimistic about AI’s role in improving decision-making, they continue to see human judgment, ethics, critical thinking and empathy as essential capabilities that must be actively protected and developed as AI becomes embedded in workplace workflows. “Human cognition is a bit like a muscle: use it or lose it,” says M

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training10.9.2026 12:35:00 CEST | Press release

Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants Training guidance is designed to prepare healthcare providers to deliver high-quality treatment experiences to patients receiving COMP360, if approved Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected commercial launch, if approved. The recipients were selected through a competitive application process based on their expertise and proven abilit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye